Eocene (EOCN) Stock Analysis
NASDAQHealthcareMedical - Pharmaceuticals
Track EOCN in your portfolio for free · Portfolio tracker
What Eocene does
Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Key metrics
ETFs linked to EOCN
Broad-market and Healthcare sector ETFs an investor holding Eocene is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how EOCN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze EOCN in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Eocene?
- Eocene trades under the ticker EOCN on NASDAQ.
- Which exchange is EOCN listed on?
- EOCN is listed on NASDAQ.
- What sector does Eocene operate in?
- Eocene is classified in the Healthcare sector (Medical - Pharmaceuticals industry).
- How can PortView help analyze EOCN in a portfolio?
- PortView shows EOCN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.